Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry

Leuk Res. 2021 Dec:111:106673. doi: 10.1016/j.leukres.2021.106673. Epub 2021 Jul 26.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / metabolism*
  • Cytarabine / therapeutic use*
  • Daunorubicin / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / metabolism
  • Leukemia, Myeloid, Acute / pathology*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / metabolism
  • Neoplasm Recurrence, Local / pathology*
  • Neoplasm, Residual / drug therapy
  • Neoplasm, Residual / metabolism
  • Neoplasm, Residual / pathology*
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / metabolism
  • Neoplastic Stem Cells / pathology*
  • Prognosis
  • Retrospective Studies
  • Young Adult

Substances

  • Biomarkers, Tumor
  • CPX-351
  • Cytarabine
  • Daunorubicin